ELSEVIER SCIENCE
IRELAND

Chemistry and Physics of Lipids
67/68 (1994) 435–439

Chemistry and Physics
of
LIPIDS

Subject Index

Volumes 67/68 (1994)

acute phase reactant, lipoprotein(a), apo(a) isoform, physiological function, angiogenesis, 411
aggregation, atherosclerosis, cell culture, desialylated lipoprotein(a), lipid accumulation, 161
angiogenesis, lipoprotein(a), apo(a) isoform, acute phase reactant, physiological function, 411
α_2-antiplasmin, plasminogen, lipoprotein(a), apolipoprotein(a), kringle domain, fibrin, t-PA, PAI-1, pro-urokinase, 353
α_2-antiplasmin, lipoprotein (a) and fibrinolysis, plasminogen activation, tissue-type plasminogen activator, 363
apheresis, lipoprotein(a), apolipoprotein(a), atherosclerosis, immunosorbent, 323
Apo B, PCFIA, Lp(a), immunoassay, fluorescence, apolipoprotein, 249
apo B-100, apolipoproteins, Lp[a], apo[a], 35
apo(a), lipoprotein(a), Lp(a), standardization of lipoprotein measurements, 257
apo(a) isoform, lipoprotein(a), acute phase reactant, physiological function, angiogenesis, 411
apo(a) kringle homolog, kringle structure, plasminogen kringle 4, protein NMR, 43
Apo-B-100 primary structure, sulfhydryls and disulfide linkages of apoB-100, free sulfhydryl of apoB on LDL, disulfide linkage of Lp[a], 99
apoB, Lp(a), arteries, plaques, immunoblotting, 271
apoB100-apo(a), triglyceride-rich Lp(a), Lp(a) secretion, primary cultures of human hepatocytes, oleate incubation with hepatocytes, 135
apolipoprotein, PCFIA, Lp(a), immunoassay, fluorescence, Apo B, 249
apolipoprotein B, lipoprotein(a), apolipoproteins, familial, hypercholsterolemia, LDL apheresis, lipoprotein turnover, atherosclerosis, 305
apolipoprotein B, lipoprotein(a), LDL-apheresis, LDL-cholesterol, 315
apolipoprotein(a), lipoprotein(a), atherosclerosis, apheresis, immunosorbent, 323
apolipoprotein(a), lipoprotein(a), atherosclerosis in transgenic mice, 19
apolipoprotein(a), lipoprotein(a), plasminogen activation, fibrinolysis, kringle domain, lysine-binding sites, lysine-fibrin carboxy-terminal residues, 369
apolipoprotein(a), plasminogen, lipoprotein(a), kringle domain, fibrin, t-PA, PAI-1, α_2-antiplasmin, pro-urokinase, 353
apolipoprotein(a), polymorphism, blacks, whites, 283
apolipoprotein(a) gene expression, tracking of Lp(a) in infancy, Lp(a) levels in children, 299
apolipoproteins, lipoprotein(a), apolipoprotein B, familial, hypercholesterolemia, LDL apheresis, lipoprotein turnover, atherosclerosis, 305
apolipoproteins, Lp[a], apo[a], apo B-100, 35
apo[a], apolipoproteins, Lp[a], apo B-100, 35
arteries, Lp(a), apoB, plaques, immunoblotting, 271
artery wall, lipoprotein retention, atherosclerosis, C56BL/6 mice, C3H/HeJ mice, 175
atherosclerosis, lipoprotein(a), apolipoprotein B, apolipoproteins, familial, hypercholesterolemia, LDL apheresis, lipoprotein turnover, 305
atherosclerosis, cell culture, desialylated lipoprotein(a), aggregation, lipid accumulation, 161
atherosclerosis, familial hypercholesterolemia, Lp[a], LDL, LDL apheresis, 331
atherosclerosis, lipoprotein(a), recombinant apo(a), low-density lipoprotein, protease, proteolysis, 25
atherosclerosis, lipoprotein retention, artery wall, C56BL/6 mice, C3H/HeJ mice, 175
atherosclerosis, lipoprotein(a), apolipoprotein(a), apheresis, immunosorbent, 323
atherosclerosis, Lp(a), ELISA, 243
atherosclerosis, Lp(a) lipoprotein, genetics, evolution, longevity, blood vessels, risk factors, 9
atherosclerosis in transgenic mice, lipoprotein(a), apolipoprotein(a), 19

B-mode ultrasonography, lipoprotein Lp[a], race, carotid atherosclerosis, 405
baboon hepatocytes, structure, kringles, native and recombinant, triglyceride-rich particles, Lp[a] quantification, phenotypes, heparin extracorporeal LDL precipitation (HELP) method, 1
baboons, Lp(a), diet response, geneic effects, 199
blacks, apolipoprotein(a), polymorphism, whites, 283
blood vessels, Lp(a) lipoprotein, genetics, evolution, longevity, atherosclerosis, risk factors, 9

0009-3084/94/$07.00 © 1994 Elsevier Science Ireland Ltd. All rights reserved.
SSDI 0009-3084(93)02297-I

body-builders, Lp[a], runners, triglycerides, cholesterol, HDL-triglycerides, 207

C3H/HeJ mice, lipoprotein retention, artery wall, atherosclerosis, C56BL/6 mice, 175
C56BL/6 mice, lipoprotein retention, artery wall, atherosclerosis, C3H/HeJ mice, 175
carotid atherosclerosis, lipoprotein Lp[a], race, B-mode ultrasonography, 405
carotid atherosclerosis, Lp(a), lipoproteins, serum lipids, cerebrovascular disease, 429
cell culture, atherosclerosis, desialylated lipoprotein(a), aggregation, lipid accumulation, 161
cerebrovascular disease, Lp(a), lipoproteins, serum lipids, carotid atherosclerosis, 429
cholesterol, Lp[a], runners, body-builders, triglycerides, HDL-triglycerides, 207
cholesterol biosynthesis, Lp(a) degradation, Lp(a) purification, familial hypercholesterolemia, 153
cholesteryl ester-rich Lp(a), post-prandial Lp(a), triglyceride-rich Lp(a), 193
cold-induced self-association, Lp(a) polymorphism, lysine-sepharose binding, fibrin binding, comparison to plasminogen, 69
comparison to plasminogen, Lp(a) polymorphism, cold-induced self-association, lysine-sepharose binding, fibrin binding, 69
coronary heart disease, lipoprotein(a), 389
cryomicroscopy, lipoprotein[a], Lp[a], electron microscopy, image processing, multivariate statistical analysis, MSA, single particles, 81

desialylated lipoprotein(a), atherosclerosis, cell culture, aggregation, lipid accumulation, 161
diet response, Lp(a), genetic effects, baboons, 199
diphenylhexatriene phospholipid, lipoprotein structure, fluorescent phospholipids, pyrene diether phosphatidylcholine, 115
disulfide linkage of Lp[a], Apo-B-100 primary structure, sulfhydryls and disulfide linkages of apoB-100, free sulfhydryl of apoB on LDL, 99

electron microscopy, lipoprotein[a], Lp[a], cryomicroscopy, image processing, multivariate statistical analysis, MSA, single particles, 81
electron microscopy, recombinant apolipoprotein(a), lipoprotein(a), hydrodynamics, protein-protein interactions, 91
ELISA, Lp(a), atherosclerosis, 243
endoplasmic reticulum, lipoprotein(a), Golgi, primary hepatocytes, 123
evolution, Lp(a) lipoprotein, genetics, longevity, blood vessels, atherosclerosis, risk factors, 9

familial, lipoprotein(a), apolipoprotein B, apolipoproteins, hypercholesterolemia, LDL apheresis, lipoprotein turnover, atherosclerosis, 305
familial hypercholesterolemia, atherosclerosis, Lp[a], LDL, LDL apheresis, 331
familial hypercholesterolemia, Lp(a) degradation, cholesterol biosynthesis, Lp(a) purification, 153
fibrin, plasminogen, lipoprotein(a), apolipoprotein(a), kringle domain, t-PA, PAI-1, α_2-antiplasmin, pro-urokinase, 353
fibrin binding, Lp(a) polymorphism, cold-induced self-association, lysine-sepharose binding, comparison to plasminogen, 69
fibrinolysis, lipoprotein(a), apolipoprotein(a), plasminogen activation, kringle domain, lysine-binding sites, lysine-fibrin carboxy-terminal residues, 369
fluorescence, PCFIA, Lp(a), immunoassay, Apo B, apolipoprotein, 249
fluorescent phospholipids, lipoprotein structure, pyrenediether phosphatidylcholine, diphenylhexatriene phospholipid, 115
fragment 2, thrombin complex, prothrombin kringle 2, α-thrombin, 59
free sulfhydryl of apoB on LDL, Apo-B-100 primary structure, sulfhydryls and disulfide linkages of apoB-100, disulfide linkage of Lp[a], 99

gender, Lp(a), sex hormones, hormone replacement therapy, 345
genetic effects, Lp(a), diet response, baboons, 199
genetics, Lp(a) lipoprotein, evolution, longevity, blood vessels, atherosclerosis, risk factors, 9
Golgi, lipoprotein(a), endoplasmic reticulum, primary hepatocytes, 123

HDL-triglycerides, Lp[a], runners, body-builders, triglycerides, cholesterol, 207
hemodialysis, renal failure, lipoprotein(a), triglycerides, survival, 419
heparin extracorporeal LDL precipitation (HELP) method, structure, kringles, native and recombinant, baboon hepatocytes, triglyceride-rich particles, Lp[a] quantification, phenotypes, 1
heritability, lipoprotein(a), phenotype, 293
hormone replacement therapy, Lp(a), gender, sex hormones, 345
hydrodynamics, recombinant apolipoprotein(a), lipoprotein(a), electron microscopy, protein-protein interactions, 91
hypercholesterolemia, lipoprotein(a), apolipoprotein B, apolipoproteins, familial, LDL apheresis, lipoprotein turnover, atherosclerosis, 305
hypertriglyceridemia, LDL, interactions, lipolysis, 105

image processing, lipoprotein[a], Lp[a], cryomicroscopy, electron microscopy, multivariate statistical analysis, MSA, single particles, 81
immunoassay, PCFIA, Lp(a), fluorescence, Apo B, apolipoprotein, 249
immunoblotting, Lp(a), apoB, arteries, plaques, 271
immunosorbent, lipoprotein(a), apolipoprotein(a), atherosclerosis, apheresis, 323
insulin-dependent diabetes mellitus, Lp(a), puberty, 223
interactions, LDL, lipolysis, hypertriglyceridemia, 105
international survey, Lp(a), standardization, 265

kringle domain, lipoprotein(a), apolipoprotein(a), plasminogen activation, fibrinolysis, lysine-binding sites, lysine-fibrin carboxy-terminal residues, 369
kringle domain, plasminogen, lipoprotein(a), apolipoprotein(a), fibrin, t-PA, PAI-1, α_2-antiplasmin, pro-urokinase, 353
kringle structure, plasminogen kringle 4, apo(a) kringle homolog, protein NMR, 43
kringles, structure, native and recombinant, baboon hepatocytes, triglyceride-rich particles, Lp[a] quantification, phenotypes, heparin extracorporeal LDL precipitation (HELP) method, 1

LDL, atherosclerosis, familial hypercholesterolemia, Lp[a], LDL apheresis, 331
LDL, interactions, lipolysis, hypertriglyceridemia, 105
LDL apheresis, atherosclerosis, familial hypercholesterolemia, Lp[a], LDL, 331
LDL apheresis, lipoprotein(a), apolipoprotein B, apolipoproteins, familial, hypercholesterolemia, lipoprotein turnover, atherosclerosis, 305
LDL apheresis, Lp(a), PTCA, restenosis, serum cholesterol, 339
LDL receptors, Lp(a) catabolism, Lp(a) in FH and FDB, Lp(a) family studies, 233
LDL-apheresis, lipoprotein(a), apolipoprotein B, LDL-cholesterol, 315
LDL-apheresis, lipoprotein(a), restenosis after PTCA, niceritrol, pravastatin, 399
LDL-cholesterol, lipoprotein(a), LDL-apheresis, apolipoprotein B, 315
lipid accumulation, atherosclerosis, cell culture, desialylated lipoprotein(a), aggregation, 161
lipolysis, LDL, interactions, hypertriglyceridemia, 105
lipoprotein(a), recombinant apo(a), low-density lipoprotein, protease, proteolysis, atherosclerosis, 25
lipoprotein(a), coronary heart disease, 389
lipoprotein (a) and fibrinolysis, α_2-antiplasmin, plasminogen activation, tissue-type plasminogen activator, 363
lipoprotein Lp[a], race, carotid atherosclerosis, B-mode ultrasonography, 405
lipoprotein retention, artery wall, atherosclerosis, C56BL/6 mice, C3H/HeJ mice, 175
lipoprotein structure, fluorescent phospholipids, pyrene diether phosphatidylcholine, diphenylhexatriene phospholipid, 115
lipoprotein turnover, lipoprotein(a), apolipoprotein B, apolipoproteins, familial, hypercholesterolemia, LDL apheresis, atherosclerosis, 305
lipoprotein(a), apo(a) isoform, acute phase reactant, physiological function, angiogenesis, 411
lipoprotein(a), apolipoprotein B, apolipoproteins, familial, hypercholesterolemia, LDL apheresis, lipoprotein turnover, atherosclerosis, 305
lipoprotein(a), apolipoprotein(a), atherosclerosis, apheresis, immunosorbent, 323
lipoprotein(a), apolipoprotein(a), atherosclerosis in transgenic mice, 19
lipoprotein(a), apolipoprotein(a), plasminogen activation, fibrinolysis, kringle domain, lysine-binding sites, lysine-fibrin carboxy-terminal residues, 369
lipoprotein(a), endoplasmic reticulum, Golgi, primary hepatocytes, 123
lipoprotein(a), hemodialysis, renal failure, triglycerides, survival, 419
lipoprotein(a), LDL-apheresis, apolipoprotein B, LDL-cholesterol, 315
lipoprotein(a), Lp(a), apo(a), standardization of lipoprotein measurements, 257
lipoprotein(a), phenotype, heritability, 293
lipoprotein(a), plasminogen, apolipoprotein(a), kringle domain, fibrin, t-PA, PAI-1, α_2-antiplasmin, pro-urokinase, 353
lipoprotein(a), recombinant apolipoprotein(a), electron microscopy, hydrodynamics, protein-protein interactions, 91
lipoprotein(a), restenosis after PTCA, LDL-apheresis, niceritrol, pravastatin, 399
lipoprotein-receptor interactions, lipoprotein[a], low-density lipoprotein, 145
lipoproteins, Lp(a), serum lipids, cerebrovascular disease, carotid atherosclerosis, 429
lipoprotein[a], low-density lipoprotein, lipoprotein-receptor interactions, 145
lipoprotein[a], Lp[a], cryomicroscopy, electron microscopy, image processing, multivariate statistical analysis, MSA, single particles, 81
longevity, Lp(a) lipoprotein, genetics, evolution, blood vessels, atherosclerosis, risk factors, 9
low-density lipoprotein, lipoprotein(a), recombinant apo(a), protease, proteolysis, atherosclerosis, 25
low-density lipoprotein, lipoprotein[a], lipoprotein-receptor interactions, 145
Lp(a), apoB, arteries, plaques, immunoblotting, 271
Lp(a), diet response, genetic effects, baboons, 199
Lp(a), ELISA, atherosclerosis, 243
Lp(a), gender, sex hormones, hormone replacement therapy, 345
Lp(a), insulin-dependent diabetes mellitus, puberty, 223
Lp(a), LDL apheresis, PTCA, restenosis, serum cholesterol, 339
Lp(a), lipoprotein(a), apo(a), standardization of lipoprotein measurements, 257
Lp(a), lipoproteins, serum lipids, cerebrovascular disease, carotid atherosclerosis, 429
Lp(a), PCFIA, immunoassay, fluorescence, Apo B, apolipoprotein, 249
Lp(a), standardization, international survey, 265
Lp(a), U937 cells, plasminogen binding, macrophage scavenger, receptor, oxidation, 167
Lp(a) and thrombolysis, myocardial infarction, plasminogen, 381
Lp(a) catabolism, LDL receptors, Lp(a) in FH and FDB, Lp(a) family studies, 233
Lp(a) degradation, cholesterol biosynthesis, Lp(a) purification, familial hypercholesterolemia, 153
Lp(a) family studies, Lp(a) catabolism, LDL receptors, Lp(a) in FH and FDB, 233

Lp(a) in FH and FDB, Lp(a) catabolism, LDL receptors, Lp(a) family studies, 233
Lp(a) levels in children, apolipoprotein(a) gene expression, tracking of Lp(a) in infancy, 299
Lp(a) lipoprotein, genetics, evolution, longevity, blood vessels, atherosclerosis, risk factors, 9
Lp(a) polymorphism, cold-induced self-association, lysine-sepharose binding, fibrin binding, comparison to plasminogen, 69
Lp(a) purification, Lp(a) degradation, cholesterol biosynthesis, familial hypercholesterolemia, 153
Lp(a) secretion, triglyceride-rich Lp(a), primary cultures of human hepatocytes, apoB100-apo(a), oleate incubation with hepatocytes, 135
Lp[a], apolipoproteins, apo[a], apo B-100, 35
Lp[a], atherosclerosis, familial hypercholesterolemia, LDL, LDL apheresis, 331
Lp[a], lipoprotein[a], cryomicroscopy, electron microscopy, image processing, multivariate statistical analysis, MSA, single particles, 81
Lp[a], runners, body-builders, triglycerides, cholesterol, HDL-triglycerides, 207
Lp[a] quantification, structure, kringles, native and recombinant, baboon hepatocytes, triglyceride-rich particles, phenotypes, heparin extracorporeal LDL precipitation (HELP) method, 1
lysine-binding sites, lipoprotein(a), apolipoprotein(a), plasminogen activation, fibrinolysis, kringle domain, lysine-fibrin carboxy-terminal residues, 369
lysine-fibrin carboxy-terminal residues, lipoprotein(a), apolipoprotein(a), plasminogen activation, fibrinolysis, kringle domain, lysine-binding sites, 369
lysine-sepharose binding, Lp(a) polymorphism, cold-induced self-association, fibrin binding, comparison to plasminogen, 69

macrophage scavenger, U937 cells, plasminogen binding, receptor, Lp(a), oxidation, 167
MSA, lipoprotein[a], Lp[a], cryomicroscopy, electron microscopy, image processing, multivariate statistical analysis, single particles, 81
multivariate statistical analysis, lipoprotein[a], Lp[a], cryomicroscopy, electron microscopy, image processing, MSA, single particles, 81
myocardial infarction, Lp(a) and thrombolysis, plasminogen, 381

native and recombinant, structure, kringles, baboon hepatocytes, triglyceride-rich particles, Lp[a] quantification, phenotypes, heparin extracorporeal LDL precipitation (HELP) method, 1
niceritrol, lipoprotein(a), restenosis after PTCA, LDL-apheresis, pravastatin, 399

oleate incubation with hepatocytes, triglyceride-rich Lp(a), Lp(a) secretion, primary cultures of human hepatocytes, apoB100-apo(a), 135
oxidation, U937 cells, plasminogen binding, macrophage scavenger, receptor, Lp(a), 167

PAI-1, plasminogen, lipoprotein(a), apolipoprotein(a), kringle domain, fibrin, t-PA, α_2-antiplasmin, pro-urokinase, 353
PCFIA, Lp(a), immunoassay, fluorescence, Apo B, apolipoprotein, 249
phenotype, lipoprotein(a), heritability, 293
phenotypes, structure, kringles, native and recombinant, baboon hepatocytes, triglyceride-rich particles, Lp[a] quantification, heparin extracorporeal LDL precipitation (HELP) method, 1
physiological function, lipoprotein(a), apo(a) isoform, acute phase reactant, angiogenesis, 411
plaques, Lp(a), apoB, arteries, immunoblotting, 271
plasminogen, lipoprotein(a), apolipoprotein(a), kringle domain, fibrin, t-PA, PAI-1, α_2-antiplasmin, pro-urokinase, 353
plasminogen, Lp(a) and thrombolysis, myocardial infarction, 381
plasminogen activation, lipoprotein (a) and fibrinolysis, α_2-antiplasmin, tissue-type plasminogen activator, 363
plasminogen activation, lipoprotein(a), apolipoprotein(a), fibrinolysis, kringle domain, lysine-binding sites, lysine-fibrin carboxy-terminal residues, 369
plasminogen binding, U937 cells, macrophage scavenger, receptor, Lp(a), oxidation, 167
plasminogen kringle 4, kringle structure, apo(a) kringle homolog, protein NMR, 43
polymorphism, apolipoprotein(a), blacks, whites, 283
post-prandial Lp(a), triglyceride-rich Lp(a), cholesteryl ester-rich Lp(a), 193
pravastatin, lipoprotein(a), restenosis after PTCA, LDL-apheresis, niceritrol, 399
primary cultures of human hepatocytes, triglyceride-rich Lp(a), Lp(a) secretion, apoB100-apo(a), oleate incubation with hepatocytes, 135
primary hepatocytes, lipoprotein(a), endoplasmic reticulum, Golgi, 123
pro-urokinase, plasminogen, lipoprotein(a), apolipoprotein(a), kringle domain, fibrin, t-PA, PAI-1, α_2-antiplasmin, 353
protease, lipoprotein(a), recombinant apo(a), low-density lipoprotein, proteolysis, atherosclerosis, 25
protein NMR, kringle structure, plasminogen kringle 4, apo(a) kringle homolog, 43
protein-protein interactions, recombinant apolipoprotein(a), lipoprotein(a), electron microscopy, hydrodynamics, 91
proteolysis, lipoprotein(a), recombinant apo(a), low-density lipoprotein, protease, atherosclerosis, 25
prothrombin kringle 2, fragment 2, thrombin complex, α-thrombin, 59
PTCA, LDL apheresis, Lp(a), restenosis, serum cholesterol, 339
puberty, Lp(a), insulin-dependent diabetes mellitus, 223
pyrene diether phosphatidylcholine, lipoprotein structure, fluorescent phospholipids, diphenylhexatriene phospholipid, 115

race, lipoprotein Lp[a], carotid atherosclerosis, B-mode ultrasonography, 405
receptor, U937 cells, plasminogen binding, macrophage scavenger, Lp(a), oxidation, 167

recombinant apo(a), lipoprotein(a), low-density lipoprotein, protease, proteolysis, atherosclerosis, 25
recombinant apolipoprotein(a), lipoprotein(a), electron microscopy, hydrodynamics, protein-protein interactions, 91
renal failure, hemodialysis, lipoprotein(a), triglycerides, survival, 419
restenosis, LDL apheresis, Lp(a), PTCA, serum cholesterol, 339
restenosis after PTCA, lipoprotein(a), LDL-apheresis, niceritrol, pravastatin, 399
risk factors, Lp(a) lipoprotein, genetics, evolution, longevity, blood vessels, atherosclerosis, 9
runners, Lp[a], body-builders, triglycerides, cholesterol, HDL-triglycerides, 207

serum cholesterol, LDL apheresis, Lp(a), PTCA, restenosis, 339
serum lipids, Lp(a), lipoproteins, cerebrovascular disease, carotid atherosclerosis, 429
sex hormones, Lp(a), gender, hormone replacement therapy, 345
single particles, lipoprotein[a], Lp[a], cryomicroscopy, electron microscopy, image processing, multivariate statistical analysis, MSA, 81
standardization, Lp(a), international survey, 265
standardization of lipoprotein measurements, lipoprotein(a), Lp(a), apo(a), 257
structure, kringles, native and recombinant, baboon hepatocytes, triglyceride-rich particles, Lp[a] quantification, phenotypes, heparin extracorporeal LDL precipitation (HELP) method, 1
sulfhydryls and disulfide linkages of apoB-100, Apo-B-100 primary structure, free sulfhydryl of apoB on LDL, disulfide linkage of Lp[a], 99
survival, hemodialysis, renal failure, lipoprotein(a), triglycerides, 419

t-PA, plasminogen, lipoprotein(a), apolipoprotein(a), kringle domain, fibrin, PAI-1, α_2-antiplasmin, pro-urokinase, 353
α-thrombin, fragment 2, thrombin complex, prothrombin kringle 2, 59
thrombin complex, fragment 2, prothrombin kringle 2, α-thrombin, 59
tissue-type plasminogen activator, lipoprotein (a) and fibrinolysis, α_2-antiplasmin, plasminogen activation, 363
tracking of Lp(a) in infancy, apolipoprotein(a) gene expression, Lp(a) levels in children, 299
triglycerides, hemodialysis, renal failure, lipoprotein(a), survival, 419
triglyceride-rich Lp(a), Lp(a) secretion, primary cultures of human hepatocytes, apoB100-apo(a), oleate incubation with hepatocytes, 135
triglyceride-rich Lp(a), post-prandial Lp(a), cholesteryl ester-rich Lp(a), 193
triglycerides, Lp[a], runners, body-builders, cholesterol, HDL-triglycerides, 207
triglyceride-rich particles, structure, kringles, native and recombinant, baboon hepatocytes, Lp[a] quantification, phenotypes, heparin extracorporeal LDL precipitation (HELP) method, 1

U937 cells, plasminogen binding, macrophage scavenger, receptor, Lp(a), oxidation, 167

whites, apolipoprotein(a), polymorphism, blacks, 283

ELSEVIER SCIENCE
IRELAND

Chemistry and Physics of Lipids
67/68 (1994) 441–442

Chemistry and Physics
of
LIPIDS

Author Index

Volumes 67/68 (1994)

Abe, A. 411
Abood, D. 419
Adamova, I.Y. 323
Afanasieva, O.I. 323
Aguilar, R. 207
Albers, J.J. 257
Aldrete, G. 223
Anglés-Cano, E. 353, 369
Armstrong, V.W. 315
Arni, R.K. 59

Berg, K. 9
Blanco-Vaca, F. 35
Bode, C. 381
Boelens, R. 43
Bok, D. 175
Bren, N. 35
Bren, N.D. 249
Brewer, H.B. 243
Bruschi, F. 345

Cardoso, G.C. 207
Chapman, J.M. 369
Chiu, W. 81
Clough, D.S. 145
Corder, C.C. 105
Cox, M. 43
Cressman, M.D. 419
Crosignani, P. 345

Daida, H. 399
Davidson, N.O. 135
Davignon, J. 167
Dudman, N.P.B. 299

Edelberg, J. 363
Edelstein, C. 135, 193
Ehnholm, C. 25
Eisenhauer, T. 315
Estlack, L.E. 123

Ferrell, R.E. 283
Fless, G.M. 69, 175
Fournier, C. 369
Frangos, M. 223
Freitag, M. 381
Fumagalli, R. 345

Gaddi, A. 305
Gaubatz, J.W. 35, 81, 145
Genest, M.S.J. 389
Ghazzaly, K.K. 145
Ghiselli, G. 305
Giroux, L.-M. 167
Gorges, R. 115
Gotto, A.M. 1, 99
Grillhofer, H. 153
Gruber, K.K. 223
Gu, Z.-W. 99
Guevara, Jr., J. 35, 207

Haberland, M.E. 175
Haffner, S.M. 223
van Heel, M. 81
Helmhold, M. 315
Henderson, O. 265
Hermetter, A. 115
Hervio, L. 369
Hixson, J.E. 123
von Hodenberg, E. 381
Hoff, H.F. 271, 419
Holguin, J.A. 207

Ishiwata, S. 399

Janjun, L. 293
Jauhiainen, M. 25
Jenner, J. 389
Junjun, W. 293
Jürgens, G. 429

Kamboh, M.I. 283
Kanemitsu, S. 339
Kanoh, T. 399
Kaptein, R. 43
Kato, K. 399
Knight, B.L. 233
Koren, E. 105

0009-3084/94/$07.00 © 1994 Elsevier Science Ireland Ltd. All rights reserved.
SSDI 0009-3084(93)02298-J

Koschinsky, M.L. 369
Kostner, G.M. 115, 153
Kottke, B.A. 35, 249
Kovanen, P.T. 25
Költringer, P. 429
Krämer, J. 243
Kreuzer, J. 175, 381
Kukharchuk, V.V. 323
Kutsumi, Y. 399

Labeur, C. 265
Lanford, R.E. 123
Laplaud, M. 369
Lawn, R.M. 19, 91
Lee, Y.J. 399
Lembertas, A.V. 91
Llinás, M. 43
Lloyd, M.B. 175
Lusis, A.J. 175
Lyakishev, A.A. 323

Maeda, S. 411
Makino, K. 411
Marcovina, S.M. 257
McConathy, W.J. 105
Meschia, M. 345
Mims, M.P. 145
Miyano, H. 399
Mokuno, H. 399
Morrisett, J.D. 35, 81, 145, 207, 345
Murakami, E. 339
Mykkänen, L. 223

Naruszewicz, M. 167

O'Neil, J. 271, 419
Nishikawa, H. 399
Noma, A. 399, 411

Ordovas, J.M. 389
Orekhov, A.N. 161
Orvanaños, O.O. 207

Padmanabhan, K. 59
Padmanabhan, K.P. 59
Paltauf, F. 115
Paoletti, R. 345
Parker, T.S. 331
Peniche, C. 207
Pestel, E. 381
Pfaffinger, D. 193
Phillips, M.L. 91
Pizzo, S.V. 363
Pokrovsky, S.N. 323
Pollitzer, W.S. 283
Posadas, C. 207
Prenner, E. 115
Pursiainen, M. 25

Raer, D.J. 243
Rainwater, D.L. 123, 199, 223
Raynaud, A.S. 207
Rickli, E. 43
Rodriguez, C.R. 389
Rosseneu, M. 265
Rothnagel, R. 81
Rouy, D. 369

Santiago, J. 223
Scanu, A.M. 135, 175, 193
Schaefer, E.J. 389
Schaller, J. 43
Schreiner, P.J. 405
Schuff-Werner, P. 315
Schumaker, V.N. 91
Seidel, D. 315
Seishima, M. 411
Seman, L.J. 389
Shimokawa, K. 411
Shire, S.J. 91
Sines, J. 81
Smejkal, G.B. 271
Snyder, M.L. 69
Soma, M.R. 345
Sommer, A. 115
Stix, M. 315
Sussekov, A.V. 323
Svitko, C.M. 283
Swanson, C. 243

Takatsu, F. 399
Takekoshi, N. 339
Tertov, V.V. 161
Trieu, V.N. 105
Tulinsky, A. 59

Usher, D.C. 243

Valdez, R. 223
Via, D.P. 145

Wang, C.-S. 105
Wang, X.L. 299
White, A.L. 123
Wilcken, D.E.L. 299
Williams, E.R. 283
Williamson, J. 223
Wilson, P.W.F. 389
Wu, T.-P. 59

Yamada, N. 399
Yamaguchi, H. 399
Yang, C.-Y. 99
Yang, M. 99
Yano, Y. 411
Yashiro, A. 271
Yiyi, Z. 293
Yokoi, H. 399

Zamora, J. 207
Zioncheck, T.F. 91